THERANEXUS EO -,25 WKN: A2H6LX ISIN: FR0013286259 Forum: Aktien Thema: Hauptdiskussion

Na das Jahr neigt sich ja zu Ende, daher müsste ja noch was Kommen....🤔😉

Gab es hier einen RS oder warum ist der Kurs von über 20 so eingebrochen? Weißt du das eventuell?

.

👋 Weiß man wann die Studie - Alzheimer kommen soll... Wirklich tolle Medikamente sind auf dem Markt Mangelware... die meisten sind zum ruhigstellen bei Auffälligkeiten... Sollten die Studien positiv ausfallen ... dann geht es ab... Merci

Theranexus and Beyond Batten Disease Foundation (BBDF) announce the signing of a worldwide exclusive license for Batten disease drug candidate BBDF-101 • The agreement covers the development and marketing of the drug following a single clinical trial due to begin in 2020. • If successful, this trial could lead directly to the drug's approval. https://www.theranexus.com/images/pdf/Theranexus_PR_signature_Accord_BBDF_VUKDEF.pdf

Schorsch, das klingt alles sehr interessant. Bist du investiert?

Hallo 🖐🖐 Cash: Total available funds as of September 30, 2019 stood at €9,542,000 compared to €10,231,000 as of June 30, 2019, reflecting effective cost control. This excludes the French Research Tax Credit for 2018 (€1.7m), which was collected at the beginning of October. THN102: This trial conducted in Europe and the United States evaluates the tolerance and efficacy of THN102 on non-motor symptoms in Parkinson's disease patients. Trial results expected in Q1 2020 THN201: This study compares the efficacy of THN201 with the standard-of-care drug in Alzheimer's disease associated neurocognitive disorders Results are expected towards the end of 2019 https://www.theranexus.com/en/

Hallo zusammen, so im Chatverlauf